Post-bariatric hypoglycemia treatment has become an essential medical solution owing to the increasing number of patients undergoing bariatric surgeries. Post-bariatric surgeries such as gastric bypass and sleeve gastrectomy can result in hypoglycemia due to gastric emptying and metabolic changes arising from reduced food consumption and absorption issues. Products such as oral antihypoglycemic agents, glucagon injections, and continuous glucose monitors help manage fasting hypoglycemia episodes and improve quality of life for post-bariatric patients. The Global Post-Bariatric Hypoglycemia Market is estimated to be valued at US$ 265.5 Mn in 2024 and is expected to exhibit a CAGR of 6.2% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the Post-Bariatric Hypoglycemia market are Vogenx, Inc.,Eiger BioPharmaceuticals,Eli Lilly and Company,Novo Nordisk,Xeris Pharmaceuticals. With the increasing number of bariatric surgeries, the demand for post-bariatric hypoglycemia treatment options is growing substantially. Major market players are investing heavily in R&D to develop novel drug formulations and delivery systems to expand their portfolio and better serve the needs of the growing patient pool globally.

The number of bariatric procedures performed worldwide has increased sharply over the past decade. According to the International Federation for the Surgery of Obesity and Metabolic Disorders, close to 700,000 bariatric surgeries were performed globally in 2020, up from 220,000 in 2015. This rapid growth of bariatric surgeries is fueling the demand for post-bariatric hypoglycemia management globally.

Key market players are actively expanding their geographic presence through acquisitions and collaborations. For instance, Novo Nordisk acquired Emisphere Technologies in 2015 to strengthen its formulation technologies portfolio. Similarly, Xeris Pharmaceuticals has collaborated with Everis Therapeutics to commercialize their ready-to-use glucagon formulation in select European markets. Such deals allow companies to leverage their partner’s local market insights and distribution networks to accelerate their international expansion plans.

Market Key Trends

One of the key trends gaining traction in the post-bariatric hypoglycemia market is the rising popularity of continuous glucose monitoring systems. Traditional finger-prick based blood glucose monitors required frequent testing and did not provide real-time glucose level monitoring. In comparison, continuous glucose monitoring systems such as implantable monitors and smart wearables provide real-time interstitial fluid glucose readings throughout the day. This allows for improved hypoglycemia detection and management for post-bariatric patients. Major players are focused on launching novel CGM devices with enhanced accuracy and usability to better serve this patient community. For instance, Abbott launched Freestyle Libre 3, its most advanced CGM system yet, in 2022.

Porter’s Analysis
Threat of new entrants: The availability of various approved therapies and presence of patent protections make it difficult for new companies to enter this market.

Bargaining power of buyers: The buyers have limited power in this market as there are limited treatment options available for post bariatric hypoglycemia.

Bargaining power of suppliers: The intellectual property protections and large R&D investments create high barriers for new suppliers to enter this market.

Threat of new substitutes: There is a steady research into new drug development but no major substitute exists currently that can replace existing treatment options.

Competitive rivalry: The market currently has limited number of approved drug options leading to moderate competition between existing players.

Geographical Regions

North America currently accounts for the largest share of the global post bariatric hypoglycemia market, in terms of value, owing to the high prevalence of obesity and bariatric surgeries in the US. According to CDC, over 42.4% of the American population is obese.

Asia Pacific is expected to exhibit the fastest growth over the forecast period in the global post bariatric hypoglycemia market supported by increasing healthcare expenditure, rising medical tourism, and growing obesity in developing nations like China and India.

What Are The Key Data Covered In This Post-Bariatric Hypoglycemia Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Post-Bariatric Hypoglycemia's growth between 2024 and 2031.

:- Accurate calculation of the size of the Post-Bariatric Hypoglycemia and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Post-Bariatric Hypoglycemia Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Post-Bariatric Hypoglycemia vendors

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

*Note:

1. Source: Coherent Market Insights, Public sources, Desk research

2. We have leveraged AI tools to mine information and compile it